Search research articles
Contact Us
Filters
Showing results (111-120 of 420) with videos related to
Page
of 42
Sort By:
International Journal of Antimicrobial Agents
|
August 4, 2004
Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001)
Jennifer M Streit, Ronald N Jones, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
August 18, 2004
Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003)
Paul R Rhomberg, Ronald N Jones, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
May 7, 2011
Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010)
Helio S Sader, Gary J Moet, David J Farrell, et al.
Diagnostic Microbiology and Infectious Disease
|
September 30, 2015
Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide
Helio S Sader, Paul R Rhomberg, David J Farrell, et al.
Diagnostic Microbiology and Infectious Disease
|
April 7, 2022
Selection of the appropriate avibactam concentration for use with ceftibuten in broth microdilution susceptibility testing
Helio S Sader, Jill Lindley, Lalitagauri M Deshpande, et al.
The Journal of Antimicrobial Chemotherapy
|
September 12, 2009
Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals
Helio S Sader, Ronald N Jones, Kerri L Rossi, et al.
Diagnostic Microbiology and Infectious Disease
|
February 18, 2010
Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008)
Helio S Sader, Holly K Becker, Gary J Moet, et al.
Diagnostic Microbiology and Infectious Disease
|
October 3, 2007
Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries
Ronald N Jones, Thomas R Fritsche, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
April 6, 2007
Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values
Ronald N Jones, Thomas R Fritsche, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
June 1, 2005
Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens
Jennifer M Streit, Helio S Sader, Thomas R Fritsche, et al.
Page
of 42
Search research articles
Search
Showing results (111-120 of 420) with videos related to
Sort By:
Page
of 42
International Journal of Antimicrobial Agents
|
August 4, 2004
Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001)
Jennifer M Streit, Ronald N Jones, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
August 18, 2004
Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003)
Paul R Rhomberg, Ronald N Jones, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
May 7, 2011
Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010)
Helio S Sader, Gary J Moet, David J Farrell, et al.
Diagnostic Microbiology and Infectious Disease
|
September 30, 2015
Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide
Helio S Sader, Paul R Rhomberg, David J Farrell, et al.
Diagnostic Microbiology and Infectious Disease
|
April 7, 2022
Selection of the appropriate avibactam concentration for use with ceftibuten in broth microdilution susceptibility testing
Helio S Sader, Jill Lindley, Lalitagauri M Deshpande, et al.
The Journal of Antimicrobial Chemotherapy
|
September 12, 2009
Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals
Helio S Sader, Ronald N Jones, Kerri L Rossi, et al.
Diagnostic Microbiology and Infectious Disease
|
February 18, 2010
Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008)
Helio S Sader, Holly K Becker, Gary J Moet, et al.
Diagnostic Microbiology and Infectious Disease
|
October 3, 2007
Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries
Ronald N Jones, Thomas R Fritsche, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
April 6, 2007
Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values
Ronald N Jones, Thomas R Fritsche, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
June 1, 2005
Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens
Jennifer M Streit, Helio S Sader, Thomas R Fritsche, et al.
Page
of 42